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Background: Despite the clinical success of vascular endothelial growth factor (VEGF) blockade in 
metastatic colorectal cancers (mCRC), resistance to anti-angiogenic drugs invariably develops. IL-8 and 
other cytokines have been implicated in development of resistance to anti-angiogenic therapy. Levocetirizine 
is a second generation H1 antihistamine with anti-inflammatory and IL-8 suppression properties. We 
conducted a phase II trial combining levocetirizine with capecitabine and bevacizumab to potentially 
overcome anti-angiogenic therapy resistance in patients with refractory mCRC. 
Methods: This was a single-center open-label prospective trial in refractory mCRC patients. Treatment 
consisted of oral capecitabine 850 mg/m2 twice daily administered as 7 days on and 7 days off, intravenous (IV) 
bevacizumab 5 mg/kg every 14 days and oral levocetirizine 5 mg daily. The primary end point was progression 
free survival (PFS) and secondary endpoints included objective response rate (ORR) and tolerability. An 
exploratory endpoint included correlation of PFS with cytokine levels. A sample size of 36 evaluable patients 
could identify a median PFS of 3.4 months at a 0.05 significance level. To examine cytokine changes related 
to levocetirizine treatment, patients were randomized to Arm A where levocetirizine was started 7 days after 
starting chemotherapy and to Arm B where levocetirizine was started 7 days prior to chemotherapy. Cytokine 
levels were measured at baseline and with each cycle of chemotherapy (up to three cycles). 
Results: Forty-seven patients were enrolled in the trial to have 36 evaluable patients. Arm A enrolled  
23 patients and Arm B enrolled 24 patients. Fifty percent of patients had progressive disease and 62% of patients 
had stable disease in each arm as best response. There was no demonstrable difference in PFS between the two 
arms (log-rank test P=0.83). Median time to progression was 3.4 months in Arm A and 3.5 months in Arm B. 
Conclusions: Median PFS in the trial was comparable to and appeared to be better than other regimens 
used in the refractory setting (e.g., median PFS of 1.9 months for regorafenib). Cytokine measurement 
with IL-8 levels did not show any correlation with progression free survival but patients with stable disease 
showed overall lower levels of IL-8 as compared to patients with progressive disease in the cytokine analysis. 
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Introduction 
Colorectal cancer is currently third most common cancer 
and third leading cause of cancer-related death in the 
United States. It is estimated that 140,250 new cases 
of colorectal cancer will be diagnosed and 50,630 men 
and women will die of colorectal cancer in 2018 (1). 
Approximately 20% of patients will have distant disease at 
the time of presentation and of the remaining, 50–60% will 
develop metastatic disease (2). Current treatment options 
for metastatic colorectal cancer include FOLFOX (5-FU/
leucovorin oxaliplatin), FOLFIRI (5-FU/leucovorin and 
irinotecan) chemotherapy with either angiogenesis inhibitor 
bevacizumab or an EGFR inhibitor such as cetuximab 
or panitumumab depending upon the RAS status (3-14). 
Combination of FOLFIRI plus aflibercept, FOLFIRI plus 
ramucirumab, regorafenib, trifluridine/tipiracil, nivolumab 
and pembrolizumab for MSI- H colorectal cancers are also 
FDA approved for second line or later in the treatment of 
metastatic colorectal cancer (13,15-21). Addition of all the 
novel agents to the current chemotherapy, has increased 
median overall survival of patients with advanced colorectal 
cancer currently approaching three years (22). Despite 
significant advancements in the management of metastatic 
colorectal cancer, prognosis of metastatic colorectal cancer 
remains poor after progression of disease on first-line 
therapy (23). 
Our study was init iated after FDA approval  of 
regorafenib but prior to FDA approvals of trifluridine/
tipiracil, nivolumab and pembrolizumab for metastatic 
refractory colorectal cancer. Patients in our trial were 
considered refractory to the available chemotherapy options 
at that time and to preserve quality of life, we decided to use 
a regimen of oral capecitabine one week on and one week 
off and IV bevacizumab every 14 days which is considered as 
clinically active, is feasible to administer and also tolerable 
to the patients (24). A capecitabine dose of 850 mg/m2 BID 
was considered since all of our patients had progression on 
full dose fluorouracil and or capecitabine chemotherapy and 
a lower dose seemed feasible to administer as maintenance 
as well as to preserve quality of life. 
Angiogenesis is required for tumor growth and 
metastases of colorectal cancer. Even though anti-
angiogenic drugs have had a significant impact on 
treatment outcomes in patients with colorectal cancers, 
eventually all patients in the metastatic setting develop 
disease progression, presumably due to tumor resistance 
to anti-angiogenic therapy and chemotherapy (25). Two 
modes of resistance to anti-angiogenic therapy have been 
proposed. Intrinsic resistance is defined by the absence 
of any beneficial effect of anti-angiogenic therapy, even a 
transitory one leading to no tumor response to therapy. 
Whereas, adaptive (evasive) resistance refers to the ability 
of the tumor, after an initial response phase, to develop 
an adaptation to circumvent specific angiogenic blockade. 
One of the mechanisms of evasive resistance to an anti-
angiogenic regimen involves upregulation of alternative 
pro-angiogenic signaling pathways. Blocking one of these 
alternate pathways may affect a tumor’s ability to continue 
to grow and metastasize (26,27). IL-8 is a cytokine, derived 
by monocytes and macrophages. Few studies have implied 
the role of IL-8 in angiogenesis as well as in causing 
resistance to anti-angiogenic chemotherapy agents. A study 
by Koch et al. demonstrated that human recombinant 
IL-8 showed angiogenic activity by inducing proliferation 
and chemotaxis of human umbilical vein endothelial cells. 
The study also showed that, antibodies to IL-8 blocked 
the angiogenic activity in human rheumatoid synovial 
tissue macrophages, demonstrating the role of IL-8 in 
angiogenesis (28). Another study by Huang et al. has shown 
that IL-8 may be responsible for causing resistance to anti-
angiogenic chemotherapy agents. Sunitinib, is an anti-
angiogenic targeted agent approved for the treatment 
of clear cell renal cell carcinoma (RCC). But, patients 
develop resistance to sunitinib within a year causing 
further progressive disease (29). This study by Huang 
et al. developed xenograft models representing sunitinib 
resistance in RCC. Sunitinib resistant tumors showed 
increased secretion of IL-8 and administration of IL-8 
antibody re-sensitized the tumors to sunitinib treatment, 
demonstrating the role of IL-8 not only in angiogenesis 
but also causing resistance to anti-angiogenic agents (30). 
IL-8 has been shown to be associated with proliferation, 
migration, angiogenesis and chemo-sensitivity in vitro and 
in vivo in colon cancer cell lines models (31). IL-8 and its 
receptor CXCR2 are demonstrated to be upregulated in 
colorectal cancer and has been shown to impact in vivo 
angiogenesis as well as migration, invasion and proliferation 
of colorectal cancer cells and hence are an excellent 
therapeutic target (32). 
Levocetirizine is a third-generation, potent, non-sedating 
anti-histamine (33,34). Levocetirizine has extensive well-
documented anti-inflammatory properties, inhibiting IL-8, 
and NF-κB in vivo (35). In vitro, levocetirizine inhibits the 
secretion of IL-6 and IL-8 and inhibits the upregulation of 
NF-κB (36).
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We conducted this trial to treat patients with refractory 
colorectal cancer with a combination regimen including 
capecitabine plus bevacizumab, an anti-angiogenic agent 
and added an IL-8 inhibitor, levocetirizine, to study the 
effects on patients’ tumor response and the systemic 
cytokine profile. The primary endpoint of the trial was 
to determine median progression-free survival in patients 
treated with this combination. The secondary endpoint 
included evaluation of tolerability of this regimen and 
an exploratory endpoint was to evaluate the relationship 
between the cytokine profile and response or resistance to 
anti-angiogenic therapy. 
Methods 
Patients and study design 
This was a randomized single institutional phase II trial. 
Eligibility criteria included histologically or cytologically 
confirmed diagnosis of CRC, measurable progressive 
disease refractory to prior therapy with fluoropyrimidine, 
oxaliplatin, irinotecan, and/or anti-angiogenic therapy 
and epidermal growth factor receptor (EGFR) inhibitor 
such as cetuximab or panitumumab for KRAS wild type 
tumors. Other inclusion criteria included adequate bone 
marrow and organ function and ECOG of <2. Patients with 
active brain metastasis, dihydropyrimidine dehydrogenase 
(DPD) deficiency, uncontrolled hypertension, proteinuria, 
unstable angina and known HIV status on highly active 
antiretroviral therapy (HAART) were excluded from the 
trial due to possible interaction of levocetirizine with 
HAART medications. The study protocol, NCT01722162 
and ethics approval was obtained from Washing University 
Institutional Review Board (IRB) and was allotted with 
Human Research Protection Office (HRPO) number 
#201303043 and all the participants gave informed consent 
before participating in the trial. 
Treatment plan 
Patients were randomized to one of two arms: patients 
in Arm A initiated the therapy with bevacizumab + 
capecitabine and started taking levocetirizine daily on Day 
8 of Cycle 1. Patients in Arm B initiated levocetirizine daily 
7 days prior to initiation of therapy with bevacizumab + 
capecitabine (Day-7).
Drug administration 
Bevacizumab was given IV on an outpatient basis at a dose 
of 5 mg/kg on Day 1 of each 2-week cycle. Capecitabine 
was given orally at a dose of 850 mg/m2 twice a day on Days 
1–7 of each 2-week cycle. Levocetirizine was also given 
orally at a dose of 5 mg daily before bed. Patients were 
followed every 2 weeks up to 30 days after progression of 
disease, or until death, whichever occurred first.
Assessment
Patients received CT scans at baseline and at every 8 weeks. 
Response and progression were evaluated by using Response 
Evaluation Criteria in Solid Tumors (RECIST) guideline 
version 1.1. All adverse events and toxicity grading report was 
done according to the revised NCI Common Terminology 
Criteria for Adverse Events (CTCAE) version 4.0. 
Statistical consideration 
The study randomization (Arm A and Arm B) was to assess 
the systemic cytokine response. The primary end point was 
progression free survival (PFS) and secondary endpoints 
included ORR and tolerability. Since all patients received 
the same overall therapy, both arms were combined in 
evaluating the incidence and severity of adverse events. 
Expected effect size, sample size and study power
Phase III randomized double-blind, placebo-controlled 
multicenter trial (CORRECT) (21), results showed that the 
median PFS in patients with metastatic colorectal cancer 
who had progression during or less than three months 
after their last standard therapy was 1.7 months. Based 
on this historical control, we proposed a favorable PFS 
of 3.4 months for our study regimen (IL-8 inhibitor plus 
capecitabine and bevacizumab). With a sample size of 36 
evaluable patients (Arms A and B combined) the study had 
the power ≥0.90 to identify a doubling of median PFS (1.7 
to 3.4 months) at a 0.05 significance level. The proposed 
sample size also had the power ≥0.80 to identify a difference 
between median PFS of 1.7 and 3.0 months at the same 
significance level. The sample size of 36 evaluable patients 
seemed adequate for the primary aim and included a margin 
for error such that the minimal detectable difference with 
36 patients is an increase of 75% in median PFS.
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Analysis plan
Cox proportional hazards models were used to estimate 
median PFS with a 95% confidence interval. Binomial 
proportions and 95% confidence intervals were used 
to describe the incidence of adverse events. Chi-square 
goodness-of-fit tests was used to test for increased severity 
(grade) of adverse events, especially of grades 3 and 4 over 
1 and 2. Tables and multidimensional plots were used to 
illustrate cytokine expression by study arm, and multiplicity 
corrected t-tests or Wilcoxon rank sum tests were used to 
test for differences between study arms. 
Correlative studies
Cytokine measurement: collection of specimen(s)
A total of 6 mL of blood was collected in 2 EDTA tubes in 
Arm A prior to initiation of capecitabine and bevacizumab 
(baseline or Cycle 1 Day 1) and prior to initiation of 
levocetirizine (Cycle 1 Day 8) and in Arm B prior to 
initiation of levocetirizine (baseline or Day-7) and prior to 
initiation of capecitabine and bevacizumab (Cycle 1 Day 1). 
Blood for cytokine measurement was also collected in both 
the arms on cycle 2 Day 1, prior to infusion of bevacizumab 
and on cycle 3 Day 1, prior to infusion of bevacizumab. 
Cytokines were measured with ELISA method from R&D 
Systems as per protocol by Ciprandi et al. (37). 
Results 
Study population
Forty-seven patients were consented for the trial from 
4/26/2013 until 7/15/2015. Five patients in Arm A and six 
patients in Arm B were not enrolled (NE) due to either 
insurance denial, disease progression prior to starting the 
trial or withdrawal of consent or a trial unrelated adverse 
event. Thirty-six evaluable patients were randomly assigned 
to Arm A and Arm B and treated per trial protocol. Table 1 
demonstrates the baseline characteristics of all 47 patients 
in Arm A and B. Median age on the trial was 60 years. 
Majority of the patients had a history of colon cancer with 
prior history of surgical resection. All the patients on the 
trial had received at least two or more lines of systemic 
chemotherapy prior to their enrollment. Nineteen percent 
of patients had history of rectal cancer and had received 
neoadjuvant chemoradiation and surgical resection as a part 
of their initial treatment. KRAS was mutated in 24 out of 47 
patients. KRAS status was unknown in one patient. Eighty 
percent of patients had more than one site of metastatic 
disease. Forty-five out of 47 patients had prior bevacizumab 
exposure and all 36 patients included in the efficacy analysis 
had prior bevacizumab therapy. 
Efficacy
All 36 patients on the trial had either progression of their disease 
or had died, hence, there were no censored (alive at last follow 
up) observations in the model of progression-free survival. 
Table 2 demonstrates efficacy and PFS in arm A and arm B. 
Median PFS was 3.36 months in Arm A and 3.5 months in Arm 
B. Twenty patients out of 36 (55%) showed stable disease. 
Figure 1 shows a Kaplan Meier survival curve demonstrating 
PFS in both Arm and Arm B. The curves overlap indicating 
similar PFS in both arms of the study. 
Toxicity
Table 3 describes all adverse events including grade 3 and 4 
adverse events related to the treatment. Treatment-related 
death did not occur in any of the arms in the trial. The 
majority of the patients tolerated this regimen very well. 
The most common side effects were grade 1 constipation, 
nausea, diarrhea, vomiting, abdominal pain, fatigue, 
headaches and cough as shown in Table 3. There were no 
grade 4 adverse events in Arm A but 1 patient in Arm B 
suffered respiratory failure which was considered grade 4 
adverse event related to progressive disease. The adverse 
event profile of the combination study regimen was within 
the expected margins of this regimen. There were no new, 
unanticipated toxicities noted.
Correlative studies
Collection of cytokine IL-8 levels were attempted on all 36 
evaluable patients. Blood samples of four patients in Arm A 
and five patients in Arm B were considered non-measurable 
due to either missing samples or due to processing delays 
of the blood samples. Figure 2 and Figure 3 show the IL-8 
levels across Arm A and Arm B respectively. One patient in 
Arm B had cytokine IL-8 levels four-fold higher than mean 
IL-8 levels across Arm B. Figure 4 shows the best response 
by IL-8 levels in both arms combined. In general IL-8 levels 
were greater in patients with progressive disease than those 
with stable disease. 
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Discussion 
Colorectal cancers are vascular tumors which rely on VEGF 
mediated angiogenesis for tumor growth and progression. 
VEGF expression by CRCs is associated with increased 
metastasis and poor prognosis (38,39). Therapeutic blockade 
of VEGF signalling has been successfully deployed as a 
treatment strategy to treat metastatic CRC (mCRC) and 
there are FDA approved drugs for the treatment of these 
cancers that affect the angiogenesis pathway. Disappointingly, 
however, all patients eventually develop resistance to anti-
angiogenic therapy and succumb to their cancer. Bevacizumab, 
Table 1 Patient baseline characteristics (N=47)
Characteristics N % Arm A Arm B
Sex
Male 29 61.7 14 15
Female 18 38.3 9 9
Median age 60 62 58
Location of primary tumor
Colon 30 63.8 15 15
Rectum 9 19.1 3 6
Rectosigmoid 8 17.0 5 3
Prior therapy
Surgery 37 78.7 18 19
Prior >2 lines of chemotherapy 36 76.6 18 18
Radiotherapy 9 19.1 3 6
Bevacizumab 45 95.8 23 22 
K-ras status
Mutated 24 51.1 14 10
Wild type 22 46.8 8 14
Unknown 1 2.1 1 –
Metastatic site
Lung only 5 10.6 1 4
Liver only 4 8.5 3 1
Multiple (peritoneum, adrenal, abdominal 
LN, chest LN, bone, brain, stomach, etc.)
38 80.9 19 19
LN, lymph nodes.
Table 2 Efficacy (N=47)
Study Arm NE patients N PD patients N [%] SD patients N [%] Total patients (N)
Median PFS in 
months
95% CI
Arm A 5 8 10 23 3.36 1.41–5.66
Arm B 6 8 10 24 3.50 1.64–4.47
Total patients 11 16 [44] 20 [55] 47 – –
NE, not evaluable; PD, progressive disease; SD, stable disease; PFS, progression free survival.
417Journal of Gastrointestinal Oncology, Vol 10, No 3 June 2019
© Journal of Gastrointestinal Oncology. All rights reserved.   J Gastrointest Oncol 2019;10(3):412-420jgo.amegroups.com
a humanized monoclonal antibody against VEGF, prevents 
interaction between VEGF and VEGFR-2, acts as an anti-
angiogenic agent and is approved along with chemotherapy 
as first and second line treatment for mCRC and contributes 
to an improvement in overall survival. Capecitabine with 
bevacizumab is an established and effective maintenance 
regimen in metastatic colorectal cancer patients after induction 
chemotherapy per phase III CAIRO 3 study (40). Our study 
showed that, this regimen was also well tolerated in refractory 
metastatic colorectal cancer patients and did not affect their 
quality of life. None of the patients in our study discontinued 
treatment due to regimen toxicity. 
A number of  mechanisms of  resistance (26)  to 
antiangiogenic therapies have been described, including 
the increased expression of various cytokines (IL-8, IL-6, 
Study Arm
A
B
0           3           6           9         12         15
B  18         10           5            3           2           1
A  18         11          5           4          1           1
Months to progression, death or last follow-up
1           0
48        51
P
ro
po
rt
io
n 
al
iv
e 
an
d 
pr
og
re
ss
io
n 
fr
ee
1.0
0.9
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0.0
Figure 1 Progression free survival: summary of deaths and 
progression events.
Table 3 Adverse events related to the treatment including grade 3 and grade 4 adverse events
Adverse events Grade 1, n (%) Grade 2, n (%) Grade 3, n (%) Grade 4, n (%)
Heart failure 1 (2.78)
Colon fistula/perforation 2 (5.56)
Small bowel obstruction 1 (2.78)
Fatigue 15 (41.67) 6 (16.67) 2 (5.56)
Bacteremia 2 (5.56)
LFT abnormalities 3 (8.34)
Anorexia 12 (33.34) 1 (2.78)
UTI 1 (2.78)
Urinary retention 1 (2.78)
Generalized muscle 
weakness
2 (5.56)
Neuropathy 2 (5.56)
Dyspnea 8 (22.23) 1 (2.78)
Respiratory failure 1 (2.77)
Hypertension 3 (8.34)
Thromboembolic event 1 (2.78)
Abdominal pain 6 (16.67)
Constipation 11 (30.56)
Diarrhea 14 (38.89) 3 (8.34)
Nausea 14 (38.89)
Vomiting 10 (27.78) 2 (5.56)
Headache 9 (25.00)
Cough 10 (27.78)
Dry skin 8 (22.23)
Hand-Foot syndrome 6 (16.67) 5 (13.89)
LFT, liver function tests; UTI, urinary tract infection.
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IL-17, etc.) (31,41,42) and increased activity of immune-
modulatory cells from the tumor microenvironment but 
there are no known biomarkers to predict sensitivity 
or resistance to anti-angiogenic therapies. We selected 
levocetirizine, a potent anti-histamine, is commercially 
available and has shown inhibition of IL-8 and NF-kB in 
in vivo and in vitro studies (36,43,44). 
In our study, fifty-five percent of patients on our study 
had stable disease as best response. This was despite 100% 
of patients with prior bevacizumab exposure. The PFS 
was 3.5 months and was similar in both the arms of the 
study. This PFS was better than other regimens used in 
the refractory setting such as regorafenib and trifluridine/
tipiracil which showed median progression free survival of 
3.2 and 2.0 months respectively (17,18). 
Evaluation of cytokine IL-8 levels in our study did not show 
any correlation with disease progression. In both arms, patients 
with stable disease had lower levels of IL-8 at baseline and 
throughout first three cycles of chemotherapy as compared to 
patients with progressive disease. We used an ELISA method 
to calculate circulating IL-8 levels, however, ELISA based 
assays have their own limitations in terms of the quality of 
antibody used as well as narrow dynamic range which may 
have falsely reduced the concentration of circulating cytokine 
in the blood due to a dilution effect (45). Also, ELISA results 
may have been less precise due to our small sample size. 
In conclusion, the regimen of levocetirizine with 
capecitabine and bevacizumab was well tolerated by 
refractory mCRC patients without any added toxicity from 
levocetirizine. The combination of levocetirizine with 
capecitabine and bevacizumab showed comparable PFS 
estimates to other commonly used regimens. We were 
unable to demonstrate an ability to overcome resistance 
to anti-angiogenic therapy using a commercially feasible 
cytokine inhibition strategy, a good avenue of investigative 
therapeutic strategy to overcome angiogenic resistance. 
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and was allotted with Human Research Protection Office 
(HRPO) number #201303043 and all the participants gave 
informed consent before participating in the trial.
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